Landscapes / Companies

Alexion Pharmaceuticals, Inc. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
4 in Phase 3
Next date
Eculizumab, Phase 3 trial completes
Drugs
15
in active trials · 38 in all
Trials
30 active
158 since 2021

Drugs15

DrugHow it worksPartnerStageNext dateDetails
Complement inhibitor
Approved 7 Dec 2026soonPhase 3 trial completes
Monoclonal antibody
Approved 15 Dec 2026soonPhase 3 trial completes
Complement factor D inhibitor
Approved 28 May 2027Phase 3 trial completes
Complement inhibitor
Approved 25 Jun 2027Phase 4 trial completes
Transthyretin stabilizer
Approved in Japan 31 Mar 2028Phase 4 trial completes
—
Phase 3 6 Dec 2027Phase 3 trial completes
—
Phase 3 —
—
Phase 3 —
—
Phase 3 —
—
Phase 2 2 Jul 2027Phase 2 trial completes
—
Phase 2 11 Oct 2027Phase 2 trial completes
Multi-specific immunoglobulin
Phase 2 11 Oct 2027Phase 2 trial completes
—
AstraZeneca
Phase 1/2 15 Aug 2029Phase 1/2 trial completes
—
Phase 1/2 27 Jan 2032Phase 1/2 trial completes
—
Phase 1 9 Aug 2027Phase 1 trial completes

About

No active trial
23 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Alexion Pharmaceuticals, Inc.

Following is part of Solo: you see every change to Alexion Pharmaceuticals, Inc. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in